FDA Panel Recommends Anti-HIV Drug for Prevention

Jon is a staff writer for Science.

On 10 May, the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) held a marathon debate about whether an anti-HIV drug on the market as a treatment should receive approval as a preventive for uninfected people. For more than 12 hours, the committee heard scientific evidence and impassioned arguments for and against, ultimately recommending that FDA approve the use of the drug Truvada for what's called pre-exposure prophylaxis (PrEP). The decision was not unanimous, and there was a protracted back and forth about how to reduce the possibility that PrEP might cause more harm than good.

Read the Full Text

Posted in Health